A Phase 1, Open-Label, Randomised, Two-Way Crossover Study to Assess the Pharmacokinetics, Relative Bioavailability and Food-Effect of a Single Dose of an Immediate Release and Extended Release Formulation of Propagermanium in Healthy Volunteers
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Irbesartan/propagermanium (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- 08 Jan 2018 According to a Dimerix Bioscience media release, today company announced top-line results from this PK trial.
- 26 Dec 2017 New trial record